ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) announced its earnings results on Monday. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($1.24), Zacks reports.
ArriVent BioPharma Price Performance
NASDAQ AVBP traded up $0.12 during mid-day trading on Friday, hitting $19.36. The stock had a trading volume of 136,991 shares, compared to its average volume of 177,573. The firm's 50 day moving average is $19.25 and its 200 day moving average is $24.46. ArriVent BioPharma has a twelve month low of $15.47 and a twelve month high of $36.37. The stock has a market capitalization of $662.36 million, a price-to-earnings ratio of -5.14 and a beta of 1.47.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on AVBP. HC Wainwright increased their target price on ArriVent BioPharma from $39.00 to $40.00 and gave the company a "buy" rating in a research report on Wednesday. B. Riley began coverage on ArriVent BioPharma in a research note on Thursday, March 20th. They issued a "buy" rating and a $37.00 price objective for the company. Finally, Guggenheim began coverage on ArriVent BioPharma in a research note on Monday, March 10th. They issued a "buy" rating and a $45.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $39.17.
Get Our Latest Stock Analysis on ArriVent BioPharma
Institutional Inflows and Outflows
An institutional investor recently bought a new position in ArriVent BioPharma stock. Dynamic Technology Lab Private Ltd bought a new position in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm bought 14,379 shares of the company's stock, valued at approximately $266,000. Institutional investors own 9.48% of the company's stock.
ArriVent BioPharma Company Profile
(
Get Free Report)
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
Further Reading
Before you consider ArriVent BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.
While ArriVent BioPharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
